GEROPHARM has received a permission to conduct an international
multi-center clinical trial of a new oral drug evogliptin for the
treatment of type 2 diabetes mellitus (phase III). The drug was licensed
to a large pharmaceutical company Dong-A ST Co., Ltd. (South Korea) in
Evogliptin belongs to the class of dipeptidyl peptidase 4 (DPP-4)
inhibitors or the class of gliptins. In clinical practice gliptins have
proved to be safe and effective oral drugs reducing the level of glucose
in patients with type 2 diabetes. Today gliptins (DPP-4 inhibitors)
occupy more than half of the world’s market of oral antidiabetic drugs,
the Russian market share is about 2,5 billion rubles. The drugs of 5
companies are now registered in this class in Russia.
The design of the international clinical trial has been planned in accordance with the requirements of international practice, and it includes the following attributes: double blinding with a double- dummy design. 11 Russian centers and 27 centers in South Korea participate in the research. The company plans to introduce evogliptin into the Russian market at the end of 2017.